Welcome to our dedicated page for Clene SEC filings (Ticker: CLNN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Clene Inc. (CLNN) SEC filings page provides access to the company’s official regulatory disclosures as a Nasdaq-listed, late clinical-stage biopharmaceutical issuer. These documents offer detailed insight into Clene’s development of CNM-Au8, its financial position, and the financing structures that support its ALS, MS, and Parkinson’s disease programs.
Investors can review current reports on Form 8-K that Clene files to describe material events. Recent 8-K filings have covered quarterly financial results and operating highlights, equity distribution agreements for at-the-market common stock offerings, prospectus supplements for additional share issuances, amendments to senior secured convertible promissory notes, and new note purchase agreements. Other 8-Ks reference press releases and scientific presentations, such as new clinical data from the REPAIR-MS and REPAIR-PD studies and regulatory updates following FDA Type C and Type B meetings.
Alongside 8-Ks, Clene’s broader SEC reporting (including Forms 10-K and 10-Q, when accessed through EDGAR) details research and development expenses, general and administrative costs, limited product and royalty revenue, and the impact of warrant and derivative liabilities. Filings also describe the terms of convertible notes, including maturity dates, interest capitalization, conversion prices into common stock, and change-of-control provisions, which are important for understanding potential dilution and capital structure.
On Stock Titan, CLNN filings are updated in near real time as they appear on EDGAR. AI-powered summaries highlight key elements of each filing, such as new financing terms, regulatory milestones, or changes in clinical development plans, helping readers quickly interpret complex legal and financial language. Users can also focus on items related to capital raises, note amendments, and other direct financial obligations that shape Clene’s runway for advancing CNM-Au8 through clinical trials and potential regulatory review.
Clene Inc. furnished an 8-K announcing third quarter 2025 financial results and recent operating highlights for the quarter ended September 30, 2025. The details are provided in a press release furnished as Exhibit 99.1 and incorporated by reference. The Item 2.02 information is furnished, not filed, and is not subject to Section 18 liabilities. The filing also lists the company’s Nasdaq-listed common stock (CLNN) and warrants (CLNNW).
Clene Inc. reported Q3 2025 results highlighting limited revenue and continued losses. Total revenue was $15 thousand (product $0, royalty $15 thousand). Loss from operations was $5.6 million, and net loss was $8.8 million (basic and diluted EPS $(0.85)).
Cash and cash equivalents were $7.9 million at September 30, 2025, down from $12.2 million at year-end. Net cash used in operating activities for the nine months was $13.7 million. The company reported a stockholders’ deficit of $12.4 million. Management stated that conditions “raise substantial doubt” about the ability to continue as a going concern, including a covenant to maintain at least $2.0 million of unrestricted cash under the 2024 senior secured convertible notes.
To support liquidity, Clene raised $3.3 million via its equity distribution agreement during Q3 and $1.5 million from new senior secured convertible notes, and subsequently generated $1.2 million more from the equity distribution. Shares outstanding were 10,333,980 as of November 10, 2025. Grant funding reduced expenses by $2.3 million (R&D) and $0.1 million (G&A) in the quarter.
Clene Inc. (CLNN) expanded its at-the-market equity program. The company previously entered into an equity distribution agreement to offer and sell common stock with an aggregate offering price of up to $25,000,000 through Canaccord Genuity LLC.
As of October 17, 2025, Clene reported prior sales of approximately $6,119,859 under this program and filed a prospectus supplement covering an additional $18,880,000 of common stock. A legal opinion from Holland & Knight LLP regarding the validity of the shares was filed as Exhibit 5.1.
Clene Inc. may offer and sell shares of common stock with a maximum aggregate gross sales price of up to $18,880,000 from time to time through Canaccord Genuity under its at‑the‑market program, as updated by Prospectus Supplement No. 3.
This amount excludes $6,119,859 of shares sold under prior supplements to date. Clene will receive the proceeds from any sales, and Canaccord may receive a commission of up to 3.0% of the gross sales price per share. The company notes it is no longer subject to the General Instruction I.B.6 sales limitations for its S‑3. On October 15, 2025, Nasdaq reported last sale prices of $8.89 for CLNN and $0.0102 for CLNNW.
Clene Inc. (CLNN) furnished an updated corporate presentation that includes preliminary unaudited figures for its cash and cash equivalents as of September 30, 2025, and the gross proceeds raised under its at-the-market equity distribution agreement from after September 30, 2025 through October 14, 2025. The presentation is attached as Exhibit 99.1.
The company notes these figures were prepared by management and remain subject to completion of financial closing procedures and potential audit adjustments. The materials are furnished under Items 2.02 and 7.01 and are not deemed “filed” for purposes of Section 18 of the Exchange Act, which means they are not subject to its liability provisions or automatically incorporated by reference into other filings.
Clene Inc. reporting person Mark Mortenson (Chief Science Officer) filed an amended Form 4 correcting an earlier filing to show an option grant for 40,000 shares of common stock. The option was granted 09/25/2025 under the Clene Inc. Amended 2020 Stock Plan with a corrected exercise price of $5.88 per share. The options vest in 12 equal monthly installments beginning 10/25/2025 and expire 09/24/2035. The amendment clarifies the exercise price only; no other transactions or changes in beneficial ownership are reported.
Clene Inc. (CLNN) reported an amended Form 4 showing an option grant to Robert Dee Etherington, President & CEO and director. The amendment corrects the exercise price to $5.88 per share for an option covering 40,000 shares of common stock granted on 09/25/2025 under the Clene Inc. Amended 2020 Stock Plan. The options vest in 12 equal monthly installments beginning 10/25/2025 and expire on 09/24/2035. The filing was signed by Jerome T. Miraglia as POA on 09/30/2025.
Clene Inc. reporting person Morgan R. Brown, Chief Financial Officer, filed an amended Form 4 to correct details of an option grant. The amendment states a stock option for 10,000 shares of common stock was granted on 09/25/2025 under the Clene Inc. Amended 2020 Stock Plan with a corrected exercise price of $5.88 per share. The options vest in 12 equal monthly installments beginning 10/25/2025 and fully vest after 12 months. The amendment corrects a previously filed Form 4 dated 09/29/2025 and was signed by POA on 09/30/2025. The filing reflects an insider compensation-related equity award with a defined vesting schedule and a specified exercise price.
Clene Inc. (CLNN) reporting person Mark Mortenson, Chief Science Officer, was granted a stock option for 40,000 shares on 09/25/2025 under the Clene Inc. Amended 2020 Stock Plan at an exercise price of $6.05 per share. The option vests in 12 equal monthly installments beginning 10/25/2025 and is exercisable through 09/24/2035. The Form 4 was filed as a single reporting person filing and signed by a power of attorney, Jerome T. Miraglia, on 09/29/2025. The filing shows the reporting person will directly own 40,000 underlying shares following the grant.
Clene Inc. insider grant: Robert Dee Etherington, President & CEO and director of Clene Inc. (CLNN), was granted an option for 40,000 shares of common stock on 09/25/2025 under the Clene Inc. Amended 2020 Stock Plan with an exercise price of $6.05 per share. The option has an exercise price of $6.05 and an expiration date of 09/24/2035.
The option vests in 12 equal monthly installments beginning 10/25/2025 (25th of each month) until fully vested. The Form 4 was filed by one reporting person and signed via POA by Jerome T. Miraglia on 09/29/2025. Following the grant, Etherington beneficially owns 40,000 underlying shares subject to the option, held directly.